Cargando…

24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension

BACKGROUND/AIMS: Fimasartan is an angiotensin type 1 receptor blocker (ARB) which has comparable efficacy and tolerability with other ARBs. The aim of this study was to evaluate 24-hour blood pressure (BP) lowering efficacy and the tolerability of the low dose fimasartan compared with valsartan in p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hae-Young, Kim, Cheol-Ho, Song, Jae-Kwan, Chae, Shung Chull, Jeong, Myung Ho, Kim, Dong-Soo, Oh, Byung-Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668394/ https://www.ncbi.nlm.nih.gov/pubmed/29032666 http://dx.doi.org/10.3904/kjim.2016.094

Ejemplares similares

Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy
por: Rhee, Moo-Yong, et al.
Publicado: (2015)

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2017)

Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial
por: Kang, Min-gu, et al.
Publicado: (2019)

Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension
por: Shin, Mi-Seung, et al.
Publicado: (2016)

Fimasartan for Remodeling after Myocardial Infarction
por: Lim, Byung-Kwan, et al.
Publicado: (2019)

Losartan/Hydrochlorothiazide Fixed Combination Versus Amlodipine Monotherapy in Korean Patients With Mild to Moderate Hypertension
por: Chung, Jin-Wook, et al.
Publicado: (2009)

Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
por: Kang, Woo Youl, et al.
Publicado: (2018)

Pharmacokinetic comparison between a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects
por: Jung, Jihyun, et al.
Publicado: (2021)

Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
por: Hong, Keun-Sik, et al.
Publicado: (2021)

Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study)
por: Chung, Woo-Baek, et al.
Publicado: (2020)

Comparison of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2018)

Effect of home blood pressure monitoring for blood pressure control in hypertensive patients taking multiple antihypertensive medications including fimasartan (the FORTE study)
por: Choi, Jung-Yeon, et al.
Publicado: (2020)

Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study
por: Oh, Gyu Chul, et al.
Publicado: (2020)

Fimasartan reduces neointimal formation and inflammation after carotid arterial injury in apolipoprotein E knockout mice
por: Kim, Jong-Ho, et al.
Publicado: (2019)

Comparison of 24-Hour Ambulatory Central Blood Pressure Reduction Efficacy Between Fixed Amlodipine or Up-Titrated Hydrochlorothiazide Plus Losartan: The K-Central Study
por: Cho, Eun Joo, et al.
Publicado: (2019)

Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain
por: Kim, Chi Kyung, et al.
Publicado: (2015)

Effects of Fimasartan/Amlodipine Fixed-Dose Combination on Left Ventricular Systolic Function and Infarct Size in Rat Myocardial Infarction Model
por: Kim, Han Byul, et al.
Publicado: (2019)

Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
por: Kim, Jihoon, et al.
Publicado: (2023)

Cardioprotective Effect of Fimasartan, a New Angiotensin Receptor Blocker, in a Porcine Model of Acute Myocardial Infarction
por: Sim, Doo Sun, et al.
Publicado: (2015)

Hyponatremia in acute heart failure: a marker of poor condition or a mediator of poor outcome?
por: Bae, Myung Hwan, et al.
Publicado: (2015)

Fimasartan attenuates renal ischemia-reperfusion injury by modulating inflammation-related apoptosis
por: Cho, Jang-Hee, et al.
Publicado: (2018)

Estimated 24-Hour Urine Sodium Excretion Is Correlated with Blood Pressure in Korean Population: 2009-2011 Korean National Health and Nutritional Examination Survey
por: Oh, Jieun, et al.
Publicado: (2014)

Fimasartan: A new armament to fight hypertension
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved In Situ Absorption Method in Rats
por: Kim, Tae Hwan, et al.
Publicado: (2018)

2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II—treatments of hypertension
por: Shin, Jinho, et al.
Publicado: (2015)

A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers
por: Kang, Woo Youl, et al.
Publicado: (2020)

2018 Korean Society of Hypertension guidelines for the management of hypertension: part I-epidemiology of hypertension
por: Kim, Hyeon Chang, et al.
Publicado: (2019)

Therapeutic Effect of Fimasartan in a Rat Model of Myocardial Infarction Evaluated by Cardiac Positron Emission Tomography with [(18)F]FPTP
por: Park, Hyukjin, et al.
Publicado: (2019)

2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction
por: Kim, Hyun Kuk, et al.
Publicado: (2020)

A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats
por: Chang, Sung-A, et al.
Publicado: (2015)

2013 Korean Society of Hypertension guidelines for the management of hypertension: part I–epidemiology and diagnosis of hypertension
por: Shin, Jinho, et al.
Publicado: (2015)

2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations
por: Shin, Jinho, et al.
Publicado: (2015)

2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension
por: Lee, Hae-Young, et al.
Publicado: (2019)

2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations
por: Kim, Kwang-il, et al.
Publicado: (2019)

Relationship of serum bilirubin concentration to kidney function and 24-hour urine protein in Korean adults
por: Shin, Ho Sik, et al.
Publicado: (2011)

Effects of Asian dust-derived particulate matter on ST-elevation myocardial infarction: retrospective, time series study
por: Lee, Suji, et al.
Publicado: (2021)

Influence of Overweight on 24-Hour Urine Chemistry Studies and Recurrent Urolithiasis in Children
por: Chung, Jae Dong, et al.
Publicado: (2012)

A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy
por: Jeon, Eun-Seok, et al.
Publicado: (2022)

Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure
por: Quan, Hailian, et al.
Publicado: (2020)

The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
por: Gu, Namyi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tnv1a8qmahjcjk9jt7l32babh3